Search

All patients had an isolated SVT confirmed by compression ultrasonography.8 The primary efficacy outcome was SVT, DVT, or PE within 90 days of diagnosis. Keywords: rivaroxaban; superficial vein thrombosis; anticoagulants; factor Xa inhibitor EN rivaroxaban superficial vein thrombosis anticoagulants factor Xa inhibitor e3 e6 4 12/27/21 20220101 NES 220101 The precise incidence of superficial vein thrombosis (SVT) is unknown. Bleeding was defined using the International Society on Thrombosis and Haemostasis criteria.9 Baseline characteristics and outcome data were extracted from the local hospital electronic patient record (EPR; Allscripts Sunrise™, Chicago, IL, USA), and anti-coagulation clinic database (DAWN xs) for each patient. [Extracted from the article]

Investigating persistent hyperferritinaemia without apparent iron overload is challenging. Even when inflammation, cirrhosis, Still's disease, fatty liver and malignancy are excluded, there remains a group of patients with unexplained hyperferritinaemia for whom rare forms of haemochromatosis (ferroportin disease) are a consideration. Preliminary results suggest that abnormal percentage glycosylation of serum ferritin is seen in some cases of genetically determined hyperferritinaemia. Serum ferritin is normally 50-81% glycosylated, but low glycosylation (20-42%) prevails in hereditary hyperferritinaemia cataract syndrome. This contrasts with hyperglycosylation (>90%) associated with the benign hyperferritinaemia related to missense L ferritin (p.Thr30Ile) mutation. Here, we describe two novel missense L ferritin variants also associated with hyperglycosylation, p.Gln26Ile and p.Ala27Val. Ferritin glycosylation, a comparatively simple measurement, can identify patients for DNA sequencing as hyperglycosylation (>90%) is associated with benign hyperferritinaemia and mutant L ferritin chain. [ABSTRACT FROM AUTHOR]

In this article, the author sheds light on his experience from patients receiving edoxaban drug at King's College Hospital in London, England. It examines prothrombin time (PT) response for patients prescribed edoxaban drug for the management of bleeding, along with determining whether the presence of edoxaban may be contributing to bleeding.